
    
      This is an open-label extension study of IMR-687 in adult patients with SCA who were
      previously participants in the Phase 2a study titled "A Phase 2a, Randomised, Double-Blind,
      Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous
      HbSS or Sickle-Î²0 Thalassemia)."

      This open-label extension study with IMR-687 will evaluate the long-term safety and
      tolerability of IMR 687 in adult SCA patients. Exploratory long-term PD parameters will also
      be examined.
    
  